Biomarin Pharmaceutical (BMRN) Share-based Compensation (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of Share-based Compensation data on file, last reported at $43.5 million in Q1 2026.

• Quarterly Share-based Compensation rose 12.07% year-over-year to $43.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $186.1 million (up 220.34% YoY) and the FY2025 annual result came in at $181.4 million, up 133.9% from the prior year.
• Share-based Compensation eased to $43.5 million in Q1 2026, from $46.9 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $105.2 million in Q3 2022 to a low of -$95.3 million in Q4 2022.
• A 5-year average of $25.5 million and a median of $38.8 million in 2025 frame the typical range for Share-based Compensation.
• The widest YoY moves for Share-based Compensation: up 1746.53% in 2022, down 162.35% in 2022.
• Tracing BMRN's Share-based Compensation over 5 years: stood at -$95.3 million in 2022, then jumped by 104.11% to $3.9 million in 2023, then advanced by 25.23% to $4.9 million in 2024, then soared by 855.65% to $46.9 million in 2025, then declined by 7.36% to $43.5 million in 2026.
• The last three Share-based Compensation figures came in at $43.5 million (Q1 2026), $46.9 million (Q4 2025), and $49.3 million (Q3 2025), per Business Quant data.